Covered recipient · General Payments record
MELINDA L TELLI
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$157,662.29
- Reported across 180 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,540.00 | 4 |
| Food and Beverage | $963.15 | 10 |
| Grant | $250.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genentech USA, Inc. | $3,872.05 | 2 |
| Daiichi Sankyo Inc. | $3,125.00 | 2 |
| Merck Sharp & Dohme Corporation | $2,745.00 | 1 |
| Gilead Sciences, Inc. | $292.98 | 3 |
| Acerta Pharma LLC | $285.86 | 2 |
| AstraZeneca UK Limited | $211.14 | 2 |
| PFIZER INC. | $106.13 | 1 |
| BioNTech SE | $81.46 | 1 |
| Genentech, Inc. | $33.53 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $250.00 | 01/31/2024 | Grant | Undisputed | 01/23/2026 | 1104554466 | CMS |
| AstraZeneca Pharmaceuticals LP | $35.86 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105490929 | CMS |
| AstraZeneca UK Limited | $135.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093999256 | CMS |
| AstraZeneca UK Limited | $76.14 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094023449 | CMS |
| BioNTech SE | $81.46 | 10/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150660454 | CMS |
| Daiichi Sankyo Inc. | $1,875.00 | 03/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089489582 | CMS |
| Daiichi Sankyo Inc. | $1,250.00 | 03/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089489580 | CMS |
| Genentech USA, Inc. | $3,670.00 | 02/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133068262 | CMS |
| Genentech USA, Inc. | $202.05 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133068266 | CMS |
| Genentech, Inc. | $33.53 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133068258 | CMS |
| Gilead Sciences, Inc. | $86.00 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133833500 | CMS |
| Gilead Sciences, Inc. | $108.85 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133833502 | CMS |
| Gilead Sciences, Inc. | $98.13 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133833504 | CMS |
| Merck Sharp & Dohme LLC | $2,745.00 | 12/04/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141574333 | CMS |
| PFIZER INC. | $106.13 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130938863 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.